CD4 and neoplasm: Loaded tumour proteins are the basis of tumour immunotherapy, and different antigen loading methods will affect the major histocompatibility complex type I and type II antigen presentation pathways, respectively, which triggers CD8+ and CD4+ T lymphocyte activation.